Morgan Stanley analyst Erin Wright raised the firm’s price target on Cardinal Health to $119 from $114 and keeps an Overweight rating on the shares. The firm was “pleased” by Cardinal’s Q4 operational upside, following varying distributor prints, and focus turns to the raised FY25 EPS guidance and new value creation strategy, which should be well-received, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAH:
- CAH Earnings: Cardinal Rises on Raised Outlook & Robust Q4 Results
- Options Volatility and Implied Earnings Moves Today, August 14, 2024
- Cardinal Health Executives to Discuss Annual Financial Results
- Cardinal Health raises FY25 EPS view to $7.55-$7.70 from at least $7.50
- Cardinal Health Reports Fourth Quarter and Fiscal Year 2024 Results and Raises Fiscal Year 2025 Guidance